JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Nature Video to Improve Older Adult Health: A Feasibility Study.

  NCT03722316

  Conditions:   Mild Dementia;   Mild Cognitive Impairment
  Interventions:   Other: Immersive Nature Video;   Other: Neutral Video
  Sponsors:   University of Southern California;   Front Porch Center for Innovation and Wellbeing
  Recruiting
• A Smartphone App to Improve Physical Activity

  NCT03417440

  Condition:   Sedentary Lifestyle
  Interventions:   Other: Physical Activity (PA) Tracker App;   Other: On Your Feet;   Other: Coach Me;   Other: Proof Positive
  Sponsors:   University of Southern California;   National Institute on Aging (NIA);   University of California, Los Angeles
  Recruiting
• Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers

  NCT04074837

  Condition:   Alzheimer Disease
  Interventions:   Drug: NNI-362;   Drug: Placebo
  Sponsors:   Neuronascent, Inc.;   National Institute on Aging (NIA)
  Recruiting
• A Phase I Study of SB26 in Healthy Volunteers

  NCT03630627

  Condition:   Healthy Volunteers
  Interventions:   Drug: SB26;   Drug: Placebo
  Sponsor:   Samsung Bioepis Co., Ltd.
  Recruiting
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

  NCT03933488

  Condition:   Healthy Participants
  Interventions:   Drug: TAK-994;   Drug: TAK-994 Placebo
  Sponsor:   Takeda
  Recruiting
• Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

  NCT03611569

  Conditions:   Healthy;   Parkinson Disease
  Interventions:   Drug: Lu AF82422;   Drug: Placebo
  Sponsor:   H. Lundbeck A/S
  Recruiting
• Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis

  NCT03334851

  Conditions:   Systemic Lupus Erythematosus;   Rheumatoid Arthritis
  Interventions:   Drug: PF-06835375;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME

  NCT03321513

  Condition:   Diabetic Macular Edema
  Interventions:   Drug: intravitreous aflibercept;   Drug: Bevacizumab + Deferred Aflibercept Group
  Sponsor:   Jaeb Center for Health Research
  Recruiting
• MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

  NCT03072927

  Condition:   Lumbar Spinal Stenosis
  Intervention:   Device: MILD
  Sponsor:   Vertos Medical, Inc.
  Recruiting
• Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

  NCT02586623

  Condition:   Symptomatic Neurogenic Orthostatic Hypotension
  Interventions:   Drug: Droxidopa capsules;   Drug: Placebo capsules
  Sponsor:   Lundbeck Northera Ltd.
  Recruiting
• Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

  NCT00443274

  Condition:   Breast Implant
  Interventions:   Other: NBIR Placeholder;   Device: 410 Arm;   Device: BIFs
  Sponsor:   Allergan
  Recruiting
• A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

  NCT04035226

  Condition:   Multiple Myeloma
  Intervention:   Other: No intervention
  Sponsors:   Janssen-Cilag Ltd.;   Legend Biotech
  Recruiting
• Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer

  NCT03778931

  Condition:   Breast Cancer
  Interventions:   Drug: Elacestrant;   Drug: Standard of Care
  Sponsor:   Radius Pharmaceuticals, Inc.
  Recruiting
• ECG Belt for CRT Response

  NCT03504020

  Condition:   Heart Failure
  Intervention:   Device: ECG Belt Research System
  Sponsor:   Medtronic Cardiac Rhythm and Heart Failure
  Recruiting
• A Pivotal Study of the Premia Spine TOPS™ System

  NCT03012776

  Conditions:   Lumbar Spinal Stenosis;   Degenerative Spondylolisthesis
  Interventions:   Device: Total Posterior Spine System (TOPS);   Procedure: Transforaminal Lumbar Interbody Fusion (TLIF)
  Sponsor:   Premia Spine
  Recruiting
• Safety, Tolerability, Pharmacokinetics and Activity of K0706

  NCT02629692

  Conditions:   Chronic Myeloid Leukemia (for Part B and C);   Healthy (For Part A)
  Interventions:   Drug: K0706;   Drug: Placebo
  Sponsor:   Sun Pharma Advanced Research Company Limited
  Recruiting
• Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma

  NCT03788746

  Condition:   Urothelial Carcinoma
  Intervention:  
  Sponsor:   AstraZeneca
  Recruiting
• Oral Factor XIa Inhibitor for the Prevention of New Ischemic Stroke in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)

  NCT03766581

  Conditions:   Acute Ischemic Stroke;   Transient Ischemic Attack (TIA)
  Interventions:   Drug: BMS-986177;   Other: BMS-986177 Placebo;   Drug: Clopidogrel;   Drug: Aspirin
  Sponsors:   Bristol-Myers Squibb;   Janssen, LP
  Recruiting
• A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis

  NCT03750643

  Condition:   Dermatitis, Atopic
  Interventions:   Drug: LY3454738;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Recruiting
• DE-117 Spectrum 5 Study

  NCT03697811

  Condition:   Primary Open-angle Glaucoma and Ocular Hypertension
  Intervention:   Drug: DE-117 Ophthalmic Solution
  Sponsor:   Santen Inc.
  Recruiting
• Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

  NCT04044664

  Condition:   Post-Traumatic Stress Disorder
  Interventions:   Drug: Placebo oral capsule;   Drug: NYX-783
  Sponsors:   Aptinyx;   Premier Research Group plc;   Massachusetts General Hospital
  Recruiting
• Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (CLARITY-2)

  NCT03968159

  Condition:   Adjunctive Treatment of Major Depressive Disorder
  Interventions:   Drug: Pimavanserin;   Drug: Placebo
  Sponsor:   ACADIA Pharmaceuticals Inc.
  Recruiting
• A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

  NCT03762850

  Condition:   Immunoglobulin A Nephropathy
  Interventions:   Drug: sparsentan;   Drug: irbesartan
  Sponsor:   Retrophin, Inc.
  Recruiting
• QUILT 2.023: A Study of N803 in Combination With Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

  NCT03520686

  Condition:   Non Small Cell Lung Cancer
  Interventions:   Drug: N-803 + Pembrolizumab;   Drug: Pembrolizumab
  Sponsors:   Altor BioScience;   NantCell, Inc.
  Recruiting
• QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer

  NCT03228667

  Conditions:   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Urothelial Carcinoma;   Head and Neck Squamous Cell Carcinoma;   Merkel Cell Carcinoma;   Melanoma;   Renal Cell Carcinoma;   Gastric Cancer;   Cervical Cancer;   Hepatocellular Carcinoma;   Microsatellite Instability;   Mismatch Repair Deficiency;   Colorectal Cancer
  Interventions:   Drug: ALT-803 + Pembrolizumab;   Drug: ALT-803 + Nivolumab;   Drug: ALT-803 + Atezolizumab;   Drug: ALT-803 + Avelumab
  Sponsor:   Altor BioScience
  Recruiting
• Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

  NCT04026165

  Condition:   Diabetic Kidney Disease
  Interventions:   Drug: SEL;   Drug: Placebo
  Sponsor:   Gilead Sciences
  Recruiting
• A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

  NCT03834753

  Conditions:   Age-related Macular Degeneration;   Neovascular Age-related Macular Degeneration;   Wet Macular Degeneration
  Interventions:   Biological: bevacizumab;   Biological: ranibizumab
  Sponsor:   Outlook Therapeutics, Inc.
  Recruiting
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

  NCT03395197

  Condition:   mCRPC
  Interventions:   Drug: Talazoparib with enzalutamide;   Drug: Placebo with enzalutamide
  Sponsors:   Pfizer;   Astellas Pharma Inc
  Recruiting
• Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

  NCT02507687

  Conditions:   Glaucoma, Open-Angle;   Ocular Hypertension
  Interventions:   Drug: Bimatoprost SR;   Drug: Sham Bimatoprost SR;   Procedure: Selective Laser Trabeculoplasty;   Procedure: Sham Selective Laser Trabeculoplasty
  Sponsor:   Allergan
  Recruiting
• Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

  NCT03891446

  Conditions:   Open-Angle Glaucoma;   Ocular Hypertension
  Intervention:   Drug: Bimatoprost SR
  Sponsor:   Allergan
  Recruiting
• Strategic Management to Optimize Response To Cardiac Resynchronization Therapy

  NCT03089281

  Condition:   Heart Failure
  Intervention:   Device: CRT-D
  Sponsor:   Boston Scientific Corporation
  Recruiting
• Tenecteplase in Stroke Patients Between 4 and 24 Hours

  NCT03785678

  Condition:   THROMBOLYSIS
  Interventions:   Biological: Tenecteplase;   Other: Placebo
  Sponsor:   Genentech, Inc.
  Recruiting
• This is a 30-month, Phase III, Multicenter, Randomized, Double-masked, Sham-injection Controlled Study to Assess the Efficacy and Safety of Multiple IVT Injections of APL-2 in Subjects With GA Secondary to AMD

  NCT03525613

  Condition:   Geographic Atrophy
  Interventions:   Drug: APL-2;   Other: Sham Procedure
  Sponsor:   Apellis Pharmaceuticals, Inc.
  Recruiting
• Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

  NCT03891862

  Condition:   Tardive Dyskinesia (TD)
  Interventions:   Drug: Valbenazine;   Drug: Placebo oral capsule
  Sponsor:   Neurocrine Biosciences
  Recruiting
• Safety and Efficacy of KPI-121 in Subjects With DED

  NCT03616899

  Condition:   Kerato Conjunctivitis Sicca
  Interventions:   Drug: KPI-121 Ophthalmic Suspension;   Drug: Vehicle
  Sponsor:   Kala Pharmaceuticals, Inc.
  Recruiting
• A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

  NCT03573297

  Conditions:   Bipolar I Disorder;   Mania;   Depression
  Interventions:   Drug: Cariprazine;   Drug: Placebo
  Sponsor:   Forest Laboratories
  Recruiting
• A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

  NCT03538691

  Condition:   Major Depressive Disorder
  Interventions:   Drug: Brexpiprazole;   Drug: Placebo;   Drug: Citalopram Hydrobromide;   Drug: Escitalopram;   Drug: Fluoxetine;   Drug: Paroxetine;   Drug: Sertraline;   Drug: Duloxetine;   Drug: Venlafaxine Extended Release Oral Capsule
  Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
  Recruiting
• A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )

  NCT03518034

  Conditions:   Hypogonadism;   Cardiovascular Diseases
  Interventions:   Drug: Testosterone;   Drug: Placebo
  Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
  Recruiting
• Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer

  NCT03499353

  Condition:   Early Breast Cancer
  Intervention:   Drug: TALAZOPARIB
  Sponsor:   Pfizer
  Recruiting
• Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

  NCT03443973

  Condition:   Alzheimer's Disease
  Interventions:   Drug: Gantenerumab;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

  NCT03226444

  Conditions:   Primary Sjögren Syndrome;   Dry Eye
  Interventions:   Drug: 0.005% Lacripep;   Drug: 0.01% Lacripep;   Drug: Placebo
  Sponsor:   TearSolutions, Inc.
  Recruiting
• Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

  NCT02876835

  Condition:   Anaemia
  Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
  Sponsor:   GlaxoSmithKline
  Recruiting
• A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

  NCT02782104

  Condition:   Depressive Disorder, Treatment-Resistant
  Intervention:   Drug: Esketamine Nasal Spray
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT02446132

  Condition:   Agitation in Patients With Dementia of the Alzheimer's Type
  Intervention:   Drug: AVP-786
  Sponsor:   Avanir Pharmaceuticals
  Recruiting
• Baroreflex Activation Therapy for Heart Failure

  NCT02627196

  Condition:   Heart Failure
  Interventions:   Device: BAROSTIM NEO® System;   Drug: Medical Management
  Sponsor:   CVRx, Inc.
  Recruiting
• Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry

  NCT01729455

  Condition:   Systemic Lupus Erythematosus
  Interventions:   Biological: BENLYSTA;   Other: SLE treatment
  Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
  Recruiting
• Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

  NCT00351611

  Condition:   Epilepsies, Partial
  Interventions:   Drug: Lyrica (pregabalin);   Drug: placebo
  Sponsor:   Pfizer
  Recruiting
• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

  NCT03093116

  Conditions:   Locally Advanced Solid Tumors;   Metastatic Solid Tumors
  Intervention:   Drug: Oral repotrectinib (TPX-0005)
  Sponsor:   Turning Point Therapeutics, Inc.
  Recruiting
• A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

  NCT03691662

  Condition:   Glaucoma and Ocular Hypertension
  Interventions:   Drug: DE-117 Ophthalmic Solution;   Drug: Timolol Maleate Ophthalmic Solution 0.5%
  Sponsor:   Santen Inc.
  Recruiting
• A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

  NCT03517722

  Condition:   Lupus Erythematosus, Systemic
  Interventions:   Drug: Placebo;   Drug: Ustekinumab (approximately 6 mg/kg);   Drug: Ustekinumab 90 mg
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia

  NCT03503318

  Condition:   Schizophrenia
  Interventions:   Drug: TV-46000 - A;   Drug: TV-46000 - B;   Drug: Placebo
  Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
  Recruiting
• Safety and Efficacy of TRx0237 in Subjects With Early Alzheimer's Disease

  NCT03446001

  Condition:   Alzheimer Disease
  Interventions:   Drug: TRx0237 8 mg/day;   Drug: Placebo;   Drug: TRx0237 16 mg/day
  Sponsor:   TauRx Therapeutics Ltd
  Recruiting